AVEO Pharmaceuticals (STU:VPA1) Total Liabilities : €73.11 Mil (As of Sep. 2022)

View and export this data going back to 2013. Start your Free Trial

What is AVEO Pharmaceuticals Total Liabilities?

AVEO Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2022 was €73.11 Mil.

AVEO Pharmaceuticals's quarterly Total Liabilities increased from Mar. 2022 (€55.64 Mil) to Jun. 2022 (€63.88 Mil) and increased from Jun. 2022 (€63.88 Mil) to Sep. 2022 (€73.11 Mil).

AVEO Pharmaceuticals's annual Total Liabilities declined from Dec. 2019 (€32.18 Mil) to Dec. 2020 (€25.99 Mil) but then increased from Dec. 2020 (€25.99 Mil) to Dec. 2021 (€52.63 Mil).

AVEO Pharmaceuticals Total Liabilities Historical Data

The historical data trend for AVEO Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals Total Liabilities Chart

AVEO Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Total Liabilities

Get a 7-Day Free Trial

76.86

48.49

32.18

25.99

52.63

AVEO Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Total Liabilities	Get a 7-Day Free Trial															49.18	52.63	55.64	63.88	73.11

AVEO Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

AVEO Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2021 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	16.577	+	(33.595	+	2.46
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	52.63

Total Liabilities	=	Total Assets (A: Dec. 2021 )	-	Total Equity (A: Dec. 2021 )
	=	93.227	-	40.595
	=	52.63

AVEO Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	42.847	+	(27.457	+	2.808
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	73.11

Total Liabilities	=	Total Assets (Q: Sep. 2022 )	-	Total Equity (Q: Sep. 2022 )
	=	102.245	-	29.133
	=	73.11

AVEO Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of AVEO Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

AVEO Pharmaceuticals (STU:VPA1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (STU:VPA1) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Winter Street, Boston, MA, USA, 02108

Website

https://www.aveooncology.com

AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.

AVEO Pharmaceuticals (STU:VPA1) Headlines

No Headlines